FMP

FMP

Enter

KYMR - Kymera Therapeutics,...

photo-url-https://images.financialmodelingprep.com/symbol/KYMR.png

Kymera Therapeutics, Inc.

KYMR

NASDAQ

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

34.37 USD

0.92 (2.68%)

Free Cash Flow

Year

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

Revenue

34.03M

72.83M

46.83M

78.59M

47.07M

57.9M

71.22M

87.61M

107.76M

132.56M

Revenue %

-

114

-35.71

67.84

-40.11

23.01

23.01

23.01

23.01

Operating Cash Flow

88.13M

-128.95M

-153.09M

-102.83M

-194.5M

-34.74M

-42.73M

-52.57M

-64.66M

-79.53M

Operating Cash Flow %

258.95

-177.05

-326.92

-130.84

-413.2

-60

-60

-60

-60

Cap Ex

-9.1M

-1.6M

-2.84M

-34.48M

-12.84M

-12.29M

-15.12M

-18.59M

-22.87M

-28.13M

Cap Ex %

-26.73

-2.19

-6.06

-43.87

-27.27

-21.22

-21.22

-21.22

-21.22

Free Cash Flow

79.03M

-130.54M

-155.92M

-137.31M

-207.34M

-47.03M

-57.85M

-71.16M

-87.53M

-107.67M

Weighted Average Cost Of Capital

Price

34.37

Beta

Diluted Shares Outstanding

75.04M

Costof Debt

4.09

Tax Rate

After Tax Cost Of Debt

4.09

Risk Free Rate

Market Risk Premium

Cost Of Equity

Total Debt

87.76M

Total Equity

2.58B

Total Capital

2.67B

Debt Weighting

3.29

Equity Weighting

96.71

Wacc

14.25

Build Up Free Cash Flow

Year

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

Revenue

34.03M

72.83M

46.83M

78.59M

47.07M

57.9M

71.22M

87.61M

107.76M

132.56M

Operating Cash Flow

88.13M

-128.95M

-153.09M

-102.83M

-194.5M

-34.74M

-42.73M

-52.57M

-64.66M

-79.53M

Cap Ex

-9.1M

-1.6M

-2.84M

-34.48M

-12.84M

-12.29M

-15.12M

-18.59M

-22.87M

-28.13M

Free Cash Flow

79.03M

-130.54M

-155.92M

-137.31M

-207.34M

-47.03M

-57.85M

-71.16M

-87.53M

-107.67M

Wacc

14.25

14.25

14.25

14.25

14.25

Pv Lfcf

-41.16M

-44.32M

-47.71M

-51.37M

-55.3M

Sum Pv Lfcf

-239.86M

Terminal Value

Growth In Perpetuity Method

Long Term Growth Rate

Wacc

14.25

Free Cash Flow T1

-109.82M

Terminal Value

-896.25M

Present Terminal Value

-460.34M

Intrinsic Value

Enterprise Value

-700.2M

Net Debt

-32.49M

Equity Value

-667.71M

Diluted Shares Outstanding

75.04M

Equity Value Per Share

-8.9

Projected DCF

-8.9 4.862%

DCF Levered

Download Excel

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2024 © Financial Modeling Prep